Thera-SAbDab

ZOLIMOMAB

> Structural Summary

Therapeutic	Zolimomab
Target	CD3E
Heavy Chain	QVQLQQSGAELARPGASVKMSCKASGYTFTRYTMHWVKQRPGQGLEWIGYINPSRGYTNYNQKFKDKATLTTDKSSSTAYMQLSSLTSEDSAVYYCARYYDDHYCLDYWGQGTTLTVSS
Light Chain	QIVLTQSPAIMSASPGEKVTMTCSASSSVSYMNWYQQKSGTSPKRWIYDTSKLASGVPAHFRGSGSGTSYSLTISGMEAEDAATYYCQQWSSNPFTFGSGTKLEIN
100% seqID Fv Structure	1sy6 [Fvs: HL]
99% seqID Fv Structure	None
95-98% seqID Fv Structure	None

100% seqID Structure	1sy6 [Fvs: HL]

> SAbPred Links

Follow these links to our prediction tools:

Model the variable domain structure with ABodyBuilder
Test for possible therapeutic developability issues with TAP
Assign canonical forms by sequence with SCALOP
Number the sequences in any numbering scheme with ANARCI: [heavy] [light]

Format	Whole mAb
Isotype	G2a
Highest Clinical Trial (June '19)	Approved
Estimated Status (June '19)	Discontinued
Recorded Developmental Technology	na
INN Year Proposed	1988
INN Year Recommended	1989
Companies Involved	Cancer Research UK, Ortho-McNeil, XOMA
Conditions Approved	na
Conditions Active	na
Conditions Discontinued	Diabetes mellitus, Graft-versus-host disease, Renal transplant rejection, Rheumatoid arthritis
Notes	Muromonab and Zolimomab are the same mAb. LC IMGT 127 is N not K as in Jain paper.

SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]

Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]